Safety and Efficacy of RAD001 in Participants With Mantle Cell Lymphoma Who Are Refractory or Intolerant to Velcade® Therapy
Public ClinicalTrials.gov record NCT00702052. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Official title
An Open-Label, Single-Arm, Phase II Study of RAD001 in Patients With Mantle Cell Lymphoma Who Are Refractory or Intolerant to Velcade® (Bortezomib)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This study was to evaluate the safety and efficacy of a daily, oral dose of 10 mg RAD001 in participants with Mantle Cell Lymphoma who were refractory or intolerant to Velcade® therapy and who had received at least one prior antineoplastic agent other than Velcade®, either separately or in combination with Velcade® (see inclusion criteria). Intolerance to Velcade® therapy was determined by the study investigator based on clinical evaluations. Participants were considered refractory to Velcade® if they have documented radiological progression on or within 12 months of the last dose of Velcade® when given alone or, on or within 12 months of the last dose of the last component of a combination therapy which included Velcade®.
Study identification
- NCT ID
- NCT00702052
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 58 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 90 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 22, 2008 (Actual)
- Primary completion
- Apr 20, 2012 (Actual)
- Completion
- Apr 20, 2012 (Actual)
- Last update posted
- May 25, 2021
2008 – 2012
United States locations
- U.S. sites
- 31
- U.S. states
- 21
- U.S. cities
- 28
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Mayo Clinic - Arizona Mayo Clinic - Scottsdale | Multiple Locations | Arizona | 85259 | — |
| Highlands Oncology Group DeptofHighlandsOncologyGrp(2) | Fayetteville | Arkansas | 72703 | — |
| Bay Area Cancer Research Dept.ofBayAreaCancerResearch | Concord | California | 94520 | — |
| City of Hope National Medical Center Dept.ofCityofHopeMedicalCtr(1) | Duarte | California | 91010-3000 | — |
| UCLA/ University of California Los Angeles Dept.of Hem/Oncology | Los Angeles | California | 90095 | — |
| University of California Davis Cancer Center Dept. of UC Davis Cancer (4) | Sacramento | California | 95817 | — |
| Rocky Mountain Cancer Centers RMCC - Denver-Midtown | Greenwood Village | Colorado | 80121 | — |
| Advanced Medical Specialties Medical Onc Hem | Miami | Florida | 33176 | — |
| Georgia Health Sciences University Dept. of MCG | Augusta | Georgia | 30912 | — |
| Northwestern University | Chicago | Illinois | 60611 | — |
| St. Francis Cancer Research Foundation Dept.ofSt.FrancisCancerRes.(2) | Beech Grove | Indiana | 46107 | — |
| Central Indiana Cancer Centers CICC - East (2) | Indianapolis | Indiana | 46227 | — |
| University of Michigan Comprehensive Cancer Center Dept of Michigan Cancer Center | Ann Arbor | Michigan | 48109-0944 | — |
| Mayo Clinic - Rochester Hematology | Rochester | Minnesota | 55905 | — |
| Washington University School Of Medicine-Siteman Cancer Ctr Medical Oncology | St Louis | Missouri | 63110 | — |
| Hackensack University Medical Center Dept ofHackensackUniversityMC | Hackensack | New Jersey | 07601 | — |
| New York University Medical Center NYU Cancer Institute | New York | New York | 10016 | — |
| East Carolina University BrodySchool of Medicine | Greenville | North Carolina | 27858 | — |
| Northwest Cancer Specialists Vancouver Cancer Center (2) | Portland | Oregon | 97210 | — |
| Kaiser Permanente Northwest Dept of Kaiser Northwest (3) | Portland | Oregon | 97227 | — |
| Fox Chase Cancer Center Regulatory Contact | Philadelphia | Pennsylvania | 19111-2497 | — |
| Western Pennsylvania Cancer Institute /Western Penn Hospital Western Pann. Cancer Inst. | Pittsburgh | Pennsylvania | 15224 | — |
| University of Pittsburgh Medical Center Hillman Cancer Center (4) | Pittsburgh | Pennsylvania | 15232 | — |
| Cancer Centers of the Carolinas CC of C -Eastside | Greenville | South Carolina | 29605 | — |
| Vanderbilt University Medical Center, Clinical Trials Center Dept. of VUMC | Nashville | Tennessee | 37212 | — |
| Baylor College of Medicine Dept. of Sammons Cancer (2) | Dallas | Texas | 75246 | — |
| University of Texas Southwestern Medical Center DeptofSimmons Cancer Center(2) | Dallas | Texas | 75390-8527 | — |
| MD Anderson Cancer Center/University of Texas Dept. of MD Anderson (10) | Houston | Texas | 77030-4009 | — |
| Tyler Cancer Center Dept.ofTylerCancerCtr. | Tyler | Texas | 75702 | — |
| Cancer Care Northwest CC Northwest- Spokane South(3) | Spokane | Washington | 99202 | — |
| West Virginia University/ Mary Babb Randolph Cancer Center | Morgantown | West Virginia | 26506 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00702052, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 25, 2021 · Synced Nov 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00702052 live on ClinicalTrials.gov.